Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy vs Chemotherapy Guided by ctDNA in Metastatic NSCLC
NCT05715229Phase 2Terminated
- Sponsor
- Hackensack Meridian Health
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab, carboplatin, Paclitaxel Micelles for Injection, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Hackensack Meridian Health. Started Sep 2023; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05715229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715229.